What is HC Wainwright’s Forecast for BCRX Q4 Earnings?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities researchers at HC Wainwright boosted their Q4 2026 earnings estimates for shares of BioCryst Pharmaceuticals in a report issued on Tuesday, June 30th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn $0.14 per share for the quarter, up from their prior forecast of $0.09. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($2.66) per share.

BCRX has been the topic of several other research reports. Citizens Jmp upped their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Needham & Company LLC decreased their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Cantor Fitzgerald upped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $21.67.

BioCryst Pharmaceuticals Trading Up 4.7%

Shares of NASDAQ BCRX opened at $10.00 on Wednesday. The stock has a market cap of $2.54 billion, a P/E ratio of -5.62 and a beta of 0.57. The business’s fifty day simple moving average is $8.91 and its 200-day simple moving average is $8.29. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $10.94.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). The business had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.20 EPS.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Phocas Financial Corp. purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $1,956,000. Vanguard Group Inc. raised its stake in BioCryst Pharmaceuticals by 6.1% during the 3rd quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock worth $165,393,000 after acquiring an additional 1,246,633 shares in the last quarter. Aberdeen Group plc purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $7,126,000. BNP Paribas Financial Markets lifted its position in BioCryst Pharmaceuticals by 21.4% in the fourth quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock valued at $19,833,000 after acquiring an additional 448,436 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in BioCryst Pharmaceuticals by 106.5% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 233,354 shares of the biotechnology company’s stock valued at $1,820,000 after acquiring an additional 120,350 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.